Observational studyGeroScience2026
Classification accuracies of plasma ptau217 vs. ptau217/Aβ1-42 for brain Aβ pathology in cognitively normal older adults.
Observational study in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05186090 (Active Gains in Brain Using Exercise During Aging), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Active Gains in Brain Using Exercise During Aging: AGUEDA Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Alzheimer´s Disease (AD) and neurodegenerative blood-based biomarkers (BBMs) are transitioning from research settings to clinical practice, where accurate interpretation is critical for their appropriate use. Particularly, the limited alignment between AD pathology and metrics of cognitive performance suggest unappreciated factors of resilience or inter-individual variability that could be influencing clinical utility and interpretation of these measures. Ninety-one cognitively normal older adults from the AGUEDA trial (NCT05186090) (71.8 ± 3.9 years; 58% females) were cross-sectionally examined for plasma Aβ42/40 SIMOA, BD-tau, GFAP, NfL, ptau217, ptau181, ptau217/Aβ1-42 IPMS and ptau217/Aβ42 SIMOA. We evaluated BBMs classification accuracies for brain amyloid-beta and examined their associations with cognitive outcomes. We then examined whether selected individual characteristics impact BBMs. Ptau217 and ptau217/Aβ42 measured by both IPMS and SIMOA exhibited strong predictive accuracy for PET Aβ positivity (AUC > 0.8) with the inclusion of some individual characteristics lowering their accuracy. Episodic memory showed a positive association with BD-tau (r = 0.29; p = 0.018), attentional/inhibitory control correlated positively with ptau217/Aβ42 SIMOA (r = 0.26; p = 0.041) and processing speed was negatively linked to GFAP (r = -0.21; p = 0.047). Age, creatinine, depressive symptoms, comorbidities and sex were associated with BD-tau, GFAP, NfL, and ptau217/Aβ42 (both IPMS and SIMOA), with standardized β values ranging from -0.27 to 0.62 (all p < 0.05). These results highlight the utility of ptau217 and ptau217/Aβ42 ratios in identifying brain amyloid pathology in cognitively normal older adults. BBMs could be used complementarily to support differential diagnosis and better understand the origins of cognitive deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.